Clearmind Medicine (NASDAQ:CMND) shared early insights from its ongoing Phase I/IIa trial of CMND-100, an investigational MEAI-based compound being evaluated for alcohol use disorder, following a June 10 webinar with study investigators from Yale and Johns Hopkins.
SLB (NYSE:SLB) announced that its OneSubsea joint venture was awarded a major engineering, procurement and construction contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire, covering subsea production systems for 13 wells.
Third Coast Bancshares (NYSE:TCBX) completed the sale of substantially all assets of its subsidiary Third Coast Commercial Capital to Gulf Coast Bank & Trust for approximately $27.5 million, generating a $3.5 million gain.
Aethlon Medical (NASDAQ:AEMD) reported that patients in the second cohort of its oncology feasibility study exhibited biological changes.
Diana Shipping (NYSE:DSX) extended its tender offer to acquire all outstanding shares of Genco Shipping & Trading (NYSE:GNK) it does not already own through July 24, 2026, after shareholders tendered 11.08 million shares.
Greenfire Resources (NYSE:GFR) agreed to acquire private thermal oil sands producer Connacher Oil and Gas for an estimated C$1.277 billion in cash, net of expected closing adjustments, expanding its production base and reserves position.
The Metals Royalty Company (NASDAQ:TMC) reported that its Mesabi Metallics iron ore royalty project in Nashwauk, Minnesota completed its first production blast on July 10, 2026, marking a step toward planned pellet production.
Ocugen (NASDAQ:OCGN) signed a binding term sheet with Roots Pharmaceutical and strategic partner Al-Dhow International Holding to negotiate an exclusive license for OCU400, its investigational modifier gene therapy for retinitis pigmentosa, across the Middle East and North Africa region.
Alkermes (NASDAQ:ALKS) reported interim results from its ongoing long-term extension study of alixorexton in adults with narcolepsy type 1 and narcolepsy type 2, showing sustained improvements in wakefulness, sleepiness and patient-reported outcomes after 24 weeks.
Ionis Pharmaceuticals (NASDAQ:IONS) announced that the first participant has been dosed in the Phase 1-2 ASCEND study evaluating ION337, an investigational RNA-targeted medicine for children with Dravet syndrome, a rare neurological disorder.
Bristol Myers Squibb (NYSE:BMY) announced that the U.S. Food and Drug Administration accepted its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone, known as MeziKd, for patients with relapsed or refractory multiple myeloma.
Q32 Bio (NASDAQ:QTTB) reported positive 36-week topline results from Part B of the Phase 2a SIGNAL-AA trial evaluating bempikibart in 33 patients with severe or very severe alopecia areata.
-1-640x359.webp&w=3840&q=75)
